CLINICAL_TRIALS
trial_result
· 2015-11-17
Clinical Trial Update: Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer [Phase 1]
Summary
This update reports results from a Phase 1 study of cabozantinib (XL184) in men with castration-resistant prostate cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Prostate Adenocarcinoma | Phase 1 | Status: COMPLETED | Results posted: 2015-11-17